Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 11/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 7/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1512966 | 1.00 | GRIK1 (0.47) | GRIK1GRIA4GRIK3GRIK5SLC1A2 | |
| SCHEMBL13780275 | 0.83 | MCL1 (0.39) | GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL359953 | 0.80 | SLC1A1 (0.45) | GRIK1GRIA4GRIK3GRIK5SLC1A2 | |
| Theanine SCHEMBL30180206 | 0.80 | SLC1A1 (0.50) | GRIK1GRIA4GRIK3GRIK5SLC1A2 | |
| Theanine SCHEMBL23581676 | 0.79 | NOD1 (0.54) | GRIK1GRIA4GRIK3GRIK5SLC1A2 | |
| SCHEMBL5079644 | 0.79 | SLC7A5 (0.43) | GRIK1GRIA4GRIK3GRIK5SLC1A2 | |
| Theanine SCHEMBL290430 | 0.79 | NOD1 (0.54) | GRIK1GRIA4GRIK3GRIK5SLC1A2 | |
| SCHEMBL21012051 | 0.79 | MCL1 (0.36) | — | |
| Theanine SCHEMBL289255 | 0.79 | NOD1 (0.54) | GRIK1GRIA4GRIK3GRIK5SLC1A2 | |
| Theanine SCHEMBL31465412 | 0.79 | NOD1 (0.54) | GRIK1GRIA4GRIK3GRIK5SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101662-B2 | Compositions with modulating agents | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-08-11 | — | — | US | claimed |
| US-8795693-B2 | Compositions with modulating agents | FOAMIX LTD. (IL) | 2014-08-05 | — | — | US | claimed |
| EP-2097065-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | Foamix Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| WO-2008152444-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | FOAMIX LTD. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | claimed |
| CN-122055375-A | Compounds and methods for treating central nervous system disorders | 美国西北大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4090670-B1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250012800-A1 | CALIBRATION SAMPLE FOR DETECTING ANTI-BARTONELLA HENSELAE ANTIBODIES | Medical Diagnostic Laboratories, L.L.C. (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-1664793-A1 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | Institute For Ethnomedicine (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005019830-A1 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | INSTITUTE FOR ETHNOMEDICINE (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050042686-A1 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | NATIONAL TROPICAL BOTANICAL GARDEN | 2005-02-24 | — | — | US | disclosed |
| US-6617332-B1 | Cyclic amidinourea derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | disclosed |
| EP-1090106-A2 | ALKYLAMINES AND THEIR PRECURSORS AS SPECIFIC MODULATORS OF HUMAN GAMMA-DELTA T CELL FUNCTION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000158-A9 | ALKYLAMINES AND THEIR PRECURSORS AS SPECIFIC MODULATORS OF HUMAN GAMMA-DELTA T CELL FUNCTION | BRIGHAM & WOMENS HOSPITAL (US) | 2000-06-22 | — | — | WO | disclosed |
| US-6031156-A | NUCLEOTIDE SEQUENCES; FOR TRANSGENIC PLANTS WITH DARKNESS AND ORGAN SPECIFIC GENE EXPRESSION | NEW YORK UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
| WO-2000000158-A2 | ALKYLAMINES AND THEIR PRECURSORS AS SPECIFIC MODULATORS OF HUMAN GAMMA-DELTA T CELL FUNCTION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | CUTA, SLTM, SMO | GRIK1 2104/4885GRIA4 2699/4885GRIK3 2137/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | GRIK1 2086/4885GRIA4 2683/4885GRIK3 1227/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | GRIK1 2086/4885GRIA4 2683/4885GRIK3 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.